Leadership

Medtech Outlook 2026: AI Integration Deepens As M&A Fuels Growth

 
• By 

Medtech leaders expect faster change in 2026 as AI integration speeds up across all business aspects, according to a Deloitte survey of medtech execs that also predicted M&A activity will remain strong in 2026. While optimism is high, uncertainties remain.

GLP-1 Sales and Fails Could Actually Inflate Gastric Balloon Market

 

Shantanu Gaur, CEO of Allurion Technologies, a company that has developed a swallowable gastric balloon, believes that GLP-1 sales could indirectly lead to increased demand for medical device-based bariatric procedures, especially as patients seek alternatives to drug side effects and weight regain.

Execs On The Move: December 1–5, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Aerogen’s Vibrating Nebulizer Could Be Breakthrough For Premature Infants

 
• By 

Aerogen, which is Ireland’s largest native medical technology firm, is in clinical trials for Aerofact, a nebulizer aimed at aiding premature infants' breathing. The technology promises easier administration of surfactant, with potential commercial rollout projected in three to four years, if succes


Execs On The Move: November 24–28, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Precise Bio Achieves Historic First 3D-Bioprinted Corneal Implant In Human, Part Of Early Trial

 
• By 

Medtech Insight spoke with Rambam Medical Center’s Michael Mimouni, who implanted the first 3D-bioprinted corneal graft in a human patient, about his hopes for Precise Bio’s approach. The patient is part of a Phase I trial evaluating PB-001 in patients with corneal edema.

What Exact-ly Is In Store For Liquid Biopsy?

 

Ahead of Exact Science’s $21bn dollar acquisition by Abbott, Medtech Insight spoke to the company’s chief medical officer, Tomasz Beer, to learn more about the company’s multi-cancer early detection offering, its wider portfolio of products and to hear more about the direction of the field.

Rarity Bioscience Sees Way Forward For superRCA Liquid Biopsy Platform, Despite Challenges

 

Entering the liquid biopsy market with a new technology remains challenging. Rarity Bioscience CEO Linus Bosaeus, is confident his company’s superRCA could help unlock the true potential of precision medicine as pharma looks more to minimal residual disease as an oncology endpoint.


Execs On The Move: November 10–14, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Digital Health Roundup: BCIs Surge Ahead, Oura Eyes BP Clearance, AI Faces New Scrutiny

Brain-computer interfaces advance toward trials and commercialization, Oura pushes for FDA-cleared blood pressure monitoring, and regulators weigh AI’s expanding role in mental health and diagnostics amid rising safety concerns.

Subsense Launches Animal Studies To Test Nonsurgical Nanoparticle Brain-Computer Interface

 
• By 

Neurotech start-up Subsense started proof-of-concept studies in mice hoping to show by late 2026 that its nonsurgical, nanoparticle-driven brain-computer interface can read and stimulate neural activity and treat conditions such as Parkinson’s and epilepsy.

Execs On The Move: November 3–7, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.


Tandem Gears Up For Mobi Tubeless Launch In 2026 After ‘Year Of Transformation’

 
• By 

Tandem Diabetes Care is positioning for growth in 2026 with the launch of its Mobi Tubeless pump following FDA clearance of its Android-compatible Mobi app while navigating multiple recalls during what CEO John Sheridan called a transformative year.

Prosthetics: Firms Like Unhindr And Esper Shape Market On the Cusp of Great Change

 

The prosthetics market is evolving due to an increase in amputees from war and disease. Unhindr has developed a novel prostetic liner that can reduce the risk of further injury, while Esper is crafting advanced hand implants for Ukraine's front-line soldiers.

Viome’s CEO To Expand Into Clinical Diagnostics ‘For Which There Are No Solutions’ With AI, RNA Test

 
• By 

Viome Life Sciences accelerates its push into clinical diagnostics with studies in colorectal cancer and a major partnership with Microsoft to scale its molecular data analysis platform. Viome leverages RNA analysis and AI to detect disease at the molecular level and personalize preventive health.

Execs On The Move: October 27–31, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.


LinusBio Extends Hair-Based Diagnostic Beyond Autism, Expands Into Japan

 
• By 

After rolling out its hair-based autism diagnostic across the US, LinusBio is expanding into Japan and testing its “molecular movie” technology for ALS and other neurological disorders, aiming to deliver the first objective biomarkers in pediatric and neuropsychiatric care.

Execs On The Move: October 20–24, 2025

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Luminoah Aims To Deliver Personalized, Data-Driven Nutrition And Dignity For Tube-Fed Patients

 
• By 

Inspired by his son’s battle with cancer, Neal Piper founded Luminoah to modernize enteral feeding. Its smart, pocket-sized pump tracks nutrition in real time to prevent malnutrition and improve quality of life for patients and caregivers.

‘From Diagnostics To Prognostics’: Google Cloud Healthcare Director Sees AI As Healthcare’s Future

 
• By 

Google Cloud healthcare lead Shweta Maniar talked with Medtech Insight about improving health monitoring, boosting regulatory collaboration, and deepening integration of technology in medical practices.